 |
|
|
| |
EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN
PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS
|
| |
| |
Ronald D'Amico,1 Paul Benn,2 Shanker Thiagarajah,3 Susan Ford,4 Eileen Birmingham,5 Ojesh Upadhyay,6 Louise Garside,3 Rodica Van Solingen-Ristea,7 Kati Vandermeulen,7 William Spreen1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, United Kingdom; 3GlaxoSmithKline, Brentford, United Kingdom; 4GlaxoSmithKline, Research Triangle Park, NC, USA; 5Janssen Research and Development, Raritan, NJ, USA; 6GlaxoSmithKline, Collegeville, PA, USA; 7Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
